Communiqués Fortress Biotech, Inc.

Actions

FBIO

US34960Q3074

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 27/07/2026			Varia. 5j.	Varia. 1 janv.
3,270 ^USD	-2,10 %		-1,80 %	-10,66 %

14/05	Fortress Biotech, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
21/04	Journey Medical Corporation conclut un accord avec un troisième groupement d'achat majeur pour l'Emrosi	RE

Communiqués

27/07	Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing	AQ
19/05	Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference	AQ
18/05	Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference	AQ
14/05	Fortress Biotech: Q1 Earnings Snapshot	AQ
14/05	Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights	AQ
13/05	Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights	AQ
06/05	Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026	AQ
04/05	Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference	AQ
21/04	Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™	AQ
31/03	Fortress Biotech: Q4 Earnings Snapshot	AQ
31/03	Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights	AQ
30/03	Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million	AQ
25/03	Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights	AQ
18/03	Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026	AQ
23/02	Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million	AQ
23/02	Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease	AQ
14/01	Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO, the First and Only Approved Treatment for Menkes Disease in the United States	AQ
13/01	Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States	AQ
15/12	Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission	AQ
10/12	Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology	AQ
17/11	Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights	AQ
14/11	Fortress Biotech: Q3 Earnings Snapshot	AQ
14/11	Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights	AQ
12/11	Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights	AQ
06/11	Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics	AQ